thalidomide has been researched along with Coagulation, Disseminated Intravascular in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thalidomide 100 mg/day stabilized multiple angiomatosis better than interferon alfa." | 7.78 | [Chronic disseminated intravascular coagulation (DIC) markers in a patient with multiple angiomatosis during treatment with anti-angiogenics: interferon α, thalidomide and lenalidomide]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Křikavová, L; Matýšková, M; Mayer, J; Navrátil, M; Nebeský, T; Neuman, C; Pour, L; Rehák, Z; Szturz, P; Tomíška, M, 2012) |
| "Thalidomide 100 mg/day stabilized multiple angiomatosis better than interferon alfa." | 3.78 | [Chronic disseminated intravascular coagulation (DIC) markers in a patient with multiple angiomatosis during treatment with anti-angiogenics: interferon α, thalidomide and lenalidomide]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Křikavová, L; Matýšková, M; Mayer, J; Navrátil, M; Nebeský, T; Neuman, C; Pour, L; Rehák, Z; Szturz, P; Tomíška, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asakura, H | 1 |
| Adam, Z | 1 |
| Pour, L | 1 |
| Matýšková, M | 1 |
| Krejčí, M | 1 |
| Tomíška, M | 1 |
| Szturz, P | 1 |
| Rehák, Z | 1 |
| Koukalová, R | 1 |
| Křikavová, L | 1 |
| Nebeský, T | 1 |
| Neuman, C | 1 |
| Navrátil, M | 1 |
| Hájek, R | 1 |
| Král, Z | 1 |
| Mayer, J | 1 |
1 review available for thalidomide and Coagulation, Disseminated Intravascular
| Article | Year |
|---|---|
[Thrombosis and DIC in hematological malignancies].
Topics: Annexin A2; Antineoplastic Agents; Asparaginase; Cytokines; Disseminated Intravascular Coagulation; | 2014 |
1 other study available for thalidomide and Coagulation, Disseminated Intravascular
| Article | Year |
|---|---|
[Chronic disseminated intravascular coagulation (DIC) markers in a patient with multiple angiomatosis during treatment with anti-angiogenics: interferon α, thalidomide and lenalidomide].
Topics: Adult; Angiogenesis Inhibitors; Angiomatosis; Biomarkers; Disseminated Intravascular Coagulation; Hu | 2012 |